Repurposing the Bis-Biguanide Alexidine in Combination with Tyrosine Kinase Inhibitors to Eliminate Leukemic Stem/Progenitor Cells in Chronic Myeloid Leukemia

SIMPLE SUMMARY: Over the past two decades, three generations of Tyrosine Kinase Inhibitors (TKIs) have been developed to target the BCR::ABL1 oncoprotein to successfully treat chronic myeloid leukemia (CML). However, to maintain a definitive remission state, the daily administration of TKIs cannot b...

Descripción completa

Detalles Bibliográficos
Autores principales: Muselli, Fabien, Mourgues, Lucas, Rochet, Nathalie, Nebout, Marielle, Guerci, Agnès, Verhoeyen, Els, Krug, Adrien, Legros, Laurence, Peyron, Jean-François, Mary, Didier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913472/
https://www.ncbi.nlm.nih.gov/pubmed/36765952
http://dx.doi.org/10.3390/cancers15030995

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913472/
https://www.ncbi.nlm.nih.gov/pubmed/36765952
http://dx.doi.org/10.3390/cancers15030995

Ejemplares similares